Group 1 - The board of directors of Wuhan Huirong Biological Technology Co., Ltd. held its 23rd meeting on August 5, 2025, with all five directors present, and the meeting complied with relevant laws and regulations [1] - The board unanimously approved the 2025 semi-annual report, confirming that it accurately reflects the company's operational status without any false statements or omissions [2][3] - The board approved the special report on the use of raised funds, ensuring compliance with relevant regulations and confirming no violations in the management and disclosure of raised funds [2][3] Group 2 - The board proposed a profit distribution plan for the first half of 2025, recommending a cash dividend of 20,157,895.70 yuan (before tax) based on a total share capital of 202,332,557 shares as of June 30, 2025 [2][3] - The profit distribution plan does not require shareholder meeting approval as it was authorized in the 2024 annual shareholder meeting [3] - The board approved the appointment of Han Jie as the rotating general manager, with the term lasting until the end of the current board's term [4] Group 3 - The board approved an investment of 170 million yuan in a project to upgrade veterinary raw material production equipment, aimed at enhancing product quality and increasing production capacity [5] - The company plans to change its registered capital from 179,194,432 yuan to 202,332,557 yuan due to the conversion of convertible bonds into shares, and to relocate its registered address [6] - The board agreed to convene the second extraordinary general meeting of shareholders on August 22, 2025 [6]

Core Viewpoint - The company reported significant growth in revenue and net profit for the first half of 2025, indicating a recovery in the animal health sector after a period of decline [1][2]. Financial Performance - The company's revenue for the first half of 2025 was approximately 822 million yuan, an increase of 88.45% year-on-year [1]. - The net profit attributable to shareholders was about 117 million yuan, marking a turnaround from losses with a year-on-year growth of 325.88% [1]. - In Q1 2025, revenue grew by 92.96% and net profit increased by 371.23% [2]. Segment Analysis - Sales revenue from chemical drug formulations increased by 54.23% year-on-year, although the gross margin decreased by 0.36% [1]. - Sales revenue from veterinary raw materials surged by 199.01% year-on-year, with a gross margin improvement of 27.14% [1]. Investment and Expansion Plans - The company plans to invest 170 million yuan in upgrading its veterinary raw material production lines, which will enhance efficiency and reduce costs [2]. - The upgrade will include the introduction of high-efficiency, automated equipment and the addition of fermentation product production lines [2]. Strategic Focus - The company is focusing on vertical integration in the raw material drug industry and horizontal expansion into pet, poultry, ruminant, and aquaculture sectors [3]. - The strategy includes developing new veterinary drugs, optimizing product performance, and expanding into international markets to mitigate domestic cyclical impacts [3].

Core Viewpoint - The company, Huibei Huisheng Biological Technology Co., Ltd., a wholly-owned subsidiary of Huisheng Biological (300871.SZ), has approved an investment of 170 million yuan for a green equipment technological transformation project in veterinary raw materials [1] Investment Project Details - The project will be executed in two phases, focusing on upgrading the existing production lines for veterinary raw materials through technological enhancements and equipment optimization [1] - The funding for the project will be sourced from the company's own funds [1] Equipment and Production Enhancements - The project aims to introduce and update high-efficiency, energy-saving, and highly automated equipment, which will enhance the production capacity of existing raw material varieties [1] - New production lines for fermentation products will be added, and measures will be taken to reduce and recycle fermentation waste [1] - Upgrades will also be made to energy storage, air compression, stirring, and wastewater treatment systems to improve energy efficiency and reduce consumption [1] Operational Efficiency - The optimization of the production line equipment composition will ensure that the capacity of upstream and downstream equipment is matched, maximizing production line capacity while reducing energy consumption and lowering labor and maintenance costs [1]

Core Viewpoint - The company, Huibei Huisheng Biological Technology Co., Ltd., a wholly-owned subsidiary of Huisheng Biological (300871.SZ), has approved an investment of 170 million yuan for the upgrade of its veterinary raw material drug production line through a green equipment technology transformation project [1] Investment Project Summary - The project will be executed in two phases, focusing on upgrading the existing technology and equipment of the veterinary raw material drug production line [1] - The funding for the project will be sourced from the company's own funds [1] Technical Enhancements - The project aims to enhance technology and optimize the composition of production line equipment, introducing new and updated high-efficiency, energy-saving, and highly automated equipment [1] - The upgrade will increase the production capacity of existing raw material drug varieties and add new production lines for fermentation products [1] - The project will also focus on reducing and resourcefully utilizing fermentation waste, as well as upgrading energy-saving measures in systems such as energy storage, air compression, stirring, and wastewater treatment [1] Production Efficiency - The optimization of the production line equipment composition will ensure that the capacity of upstream and downstream equipment is matched, maximizing production line capacity while reducing energy consumption and lowering labor and maintenance costs [1]

Group 1 - The company, Huibei Huisheng Biological Technology Co., Ltd., a wholly-owned subsidiary of Huisheng Biological, plans to invest 170 million yuan in a green equipment technological transformation project for veterinary raw materials [2] - The project will upgrade and transform the existing technology and equipment of the company's veterinary raw material production line in two phases [2] - In the semi-annual report for 2025, the company reported a net profit attributable to shareholders of 117 million yuan, marking a turnaround from losses in the previous year [2] Group 2 - The company intends to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders [2]

Group 1 - The company, Huisheng Biological, announced the convening of its 23rd meeting of the third board of directors on August 5, 2025, to discuss the appointment of a rotating general manager [2] - For the year 2024, the revenue composition of Huisheng Biological is as follows: veterinary raw materials and preparations account for 93.02%, while other segments account for 6.98% [2]

Group 1 - The company announced the implementation of a rotating general manager system, with Mr. Han Jie continuing in this role as approved by the board's nomination committee [2] - For the year 2024, the company's revenue composition is as follows: veterinary raw materials and formulations account for 93.02%, while other segments account for 6.98% [2]

智通财经APP讯，回盛生物(300871.SZ)公告，公司董事会、监事会审议通过了《关于投资建设兽用原料 药绿色设备技改项目的议案》，同意全资子公司湖北回盛生物科技有限公司投资建设兽用原料药绿色设 备技改项目。项目投资金额预计1.7亿元，分两期对公司现有兽用原料药生产线技术及设备进行升级改 造。 公告称，通过分两期系统性改造现有生产线，引入高效节能与自动化装备，实现兽用原料药产品产能的 提升，拓展发酵类产品管线，优化产品结构。 ...

Group 1 - The company, Huisheng Biological, announced the approval of an investment project for the construction of green equipment for veterinary raw materials [1] - The total investment for the project is estimated at 170 million yuan, which will be executed in two phases to upgrade the existing production line technology and equipment [1] - The project aims to systematically transform the current production line by introducing efficient, energy-saving, and automated equipment to enhance the production capacity of veterinary raw materials and optimize the product structure [1]

Group 1 - The core viewpoint of the article highlights the significant growth in the financial performance of 回盛生物, with a reported revenue of approximately 822 million yuan for the first half of 2025, representing an increase of 88.45% year-on-year [1] - The net profit attributable to shareholders for the same period is approximately 117 million yuan, contrasting with a net loss of about 51.88 million yuan in the same period of 2024 [1] - The basic earnings per share for the first half of 2025 is reported at 0.6622 yuan, compared to a loss of 0.3127 yuan per share in the previous year [1] Group 2 - As of the report's release, the market capitalization of 回盛生物 stands at 5 billion yuan [1]